{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:07:42Z","timestamp":1788952062066,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["LINEA 3\/51_25"],"award-info":[{"award-number":["LINEA 3\/51_25"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003197","name":"Italian Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015277","name":"Roche UK Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clbc.2026.07.035","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:11:35Z","timestamp":1785539495000},"page":"145-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CDK4\/6i in the Underrepresented Histological Subtypes of HR\u00b1\/HER2- Metastatic Breast Cancer: A Real-World Cohort Study of Effectiveness and Safety"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6078-4271","authenticated-orcid":false,"given":"Claudia","family":"von Arx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Piezzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Lauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Calderaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Tafuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Verrazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Di Monda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa D\u2019aulisio","family":"Garigliota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Buonaiuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Buono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cianniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Cerillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Di Rienzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Nuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Pacilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Parola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Pensabene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Poggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelino","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clbc.2026.07.035_bib0001","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/his.14091","article-title":"The 2019 World Health Organization classification of tumours of the breast","volume":"77","author":"Tan","year":"2020","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.035_bib0002","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/path.2407","article-title":"Refinement of breast cancer classification by molecular characterization of histological special types","volume":"216","author":"Weigelt","year":"2008","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.035_bib0003","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10549-013-2740-6","article-title":"Genomic profiling of histological special types of breast cancer","volume":"142","author":"Horlings","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.035_bib0004","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive molecular portraits of invasive lobular breast cancer","volume":"163","author":"Ciriello","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.clbc.2026.07.035_bib0005","unstructured":"SEER Cancer Stat Facts: Invasive Lobular Carcinoma. Bethesda, MD: National Cancer Institute. https:\/\/seer.cancer.gov\/statfacts\/html\/ilc.html. Accessed Janaury 8, 2026."},{"issue":"20","key":"10.1016\/j.clbc.2026.07.035_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70061","article-title":"Lobular breast cancer statistics, 2025","volume":"131","author":"Giaquinto","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2026.07.035_bib0007","doi-asserted-by":"crossref","DOI":"10.1186\/bcr767","article-title":"Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome","volume":"6","author":"Arpino","year":"2004","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.035_bib0008","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive molecular portraits of invasive lobular breast cancer","volume":"163","author":"Ciriello","year":"2015","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.035_bib0009","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.seminoncol.2019.03.002","article-title":"Invasive lobular breast cancer: a review of pathogenesis, diagnosis, management, and future directions of early stage disease","volume":"46","author":"Thomas","year":"2019","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.035_bib0010","doi-asserted-by":"crossref","first-page":"e943","DOI":"10.1002\/onco.13734","article-title":"Comprehensive review of molecular mechanisms and clinical features of invasive lobular cancer","volume":"26","author":"Pramod","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.035_bib0011","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10549-012-2233-z","article-title":"Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer","volume":"136","author":"Lips","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"22","key":"10.1016\/j.clbc.2026.07.035_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15225491","article-title":"Lobular carcinoma of the breast: a comprehensive review with translational insights","volume":"15","author":"Batra","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.clbc.2026.07.035_bib0013","doi-asserted-by":"crossref","first-page":"8243","DOI":"10.1245\/s10434-025-17862-0","article-title":"Impact of neoadjuvant chemotherapy on surgical outcomes and conversion to node-negativity in invasive lobular breast cancer: analysis of molecularly high-risk tumors by histologic subtype on the I-SPY2 clinical trial","volume":"32","author":"Mukhtar","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.07.035_bib0014","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41523-019-0104-z","article-title":"ESR1 mutations in metastatic lobular breast cancer patients","volume":"5","author":"Desmedt","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.035_bib0015","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/path.1908","article-title":"PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma","volume":"208","author":"Buttitta","year":"2006","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.035_bib0016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/annonc\/mdy497","article-title":"Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer","volume":"30","author":"Sokol","year":"2019","journal-title":"Ann Oncol"},{"issue":"813","key":"10.1016\/j.clbc.2026.07.035_bib0017","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adq5492","article-title":"NF1-depleted ER+ breast cancers are differentially sensitive to CDK4\/6 inhibitors","volume":"17","author":"Zheng","year":"2025","journal-title":"Sci Transl Med"},{"issue":"20","key":"10.1016\/j.clbc.2026.07.035_bib0018","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1158\/0008-5472.CAN-21-3186","article-title":"A distinct chromatin State drives therapeutic resistance in invasive lobular breast cancer","volume":"82","author":"Nardone","year":"2022","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.clbc.2026.07.035_bib0019","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1158\/0008-5472.CAN-22-2594","article-title":"A unique FOXA1-associated chromatin State dictates therapeutic resistance in lobular breast cancer","volume":"82","author":"Blawski","year":"2022","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.035_bib0020","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1158\/0008-5472.CAN-13-2779","article-title":"Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response","volume":"74","author":"Sikora","year":"2014","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.035_bib0021","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13058-018-1041-8","article-title":"Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer","volume":"20","author":"Du","year":"2018","journal-title":"Breast Cancer Res"},{"issue":"23","key":"10.1016\/j.clbc.2026.07.035_bib0022","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1158\/1078-0432.CCR-20-2268","article-title":"Characterization of stromal tumor-infiltrating lymphocytes and genomic alterations in metastatic lobular breast cancer","volume":"26","author":"Richard","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.clbc.2026.07.035_bib0023","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.035_bib0024","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.035_bib0025","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.clbc.2026.07.035_bib0026","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with Fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Jr","year":"2017","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clbc.2026.07.035_bib0027","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2026.07.035_bib0028","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with Ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clbc.2026.07.035_bib0029","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.07.035_bib0030","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.breast.2020.09.006","article-title":"Clinicopathological characteristics and prognosis of breast cancer with special histological types: a surveillance, epidemiology, and end results database analysis","volume":"54","author":"Han","year":"2020","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.035_bib0031","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10549-020-05861-6","article-title":"Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type","volume":"184","author":"Kim","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.035_bib0032","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1055\/s-0043-109374","article-title":"Distinct pattern of metastases in patients with invasive lobular carcinoma of the breast","volume":"77","author":"Mathew","year":"2017","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.035_bib0033","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","article-title":"Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI\/ESR, and EUSOMA)","volume":"51","author":"Vaz","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"282","key":"10.1016\/j.clbc.2026.07.035_bib0034","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"10226","key":"10.1016\/j.clbc.2026.07.035_bib0035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future","volume":"395","author":"Spring","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.035_bib0036","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","article-title":"A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial","volume":"36","author":"Hortobagyi","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.035_bib0037","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2026.07.035_bib0038","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.breast.2021.12.015","article-title":"The emerging role of real-world data in advanced breast cancer therapy: recommendations for collaborative decision-making","volume":"61","author":"Cottu","year":"2022","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.035_bib0039","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-19-0751","article-title":"Biomarker analyses of response to cyclin-dependent kinase 4\/6 inhibition and endocrine therapy in women with treatment-na\u00efve metastatic breast cancer","volume":"26","author":"Finn","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.clbc.2026.07.035_bib0040","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/jnci\/djaa071","article-title":"Overall survival of CDK4\/6-inhibitor-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis","volume":"112","author":"Schettini","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.035_bib0041","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","article-title":"CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis","volume":"21","author":"Gao","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.035_bib0042","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-020-05528-2","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials","volume":"180","author":"Li","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"10.1016\/j.clbc.2026.07.035_bib0043","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.3390\/ijms21176400","article-title":"Progression-free survival and overall survival of CDK 4\/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis","volume":"21","author":"Piezzo","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.clbc.2026.07.035_bib0044","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/cncr.34675","article-title":"Overall survival associated with CDK4\/6 inhibitors in patients with HR+\/HER2- metastatic breast cancer in the United States: a SEER-Medicare population-based study","volume":"129","author":"Goyal","year":"2023","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.clbc.2026.07.035_bib0045","doi-asserted-by":"crossref","first-page":"8488","DOI":"10.3390\/ijms24108488","article-title":"Abemaciclib, Palbociclib, and Ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer","volume":"24","author":"Cejuela","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.035_bib0046","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.18632\/aging.206257","article-title":"Updated efficacy and safety of CDK4\/6 inhibitors plus endocrine therapy in elderly women with HR+\/HER-2 metastatic or advanced breast cancer: patient-level network meta-analysis","volume":"17","author":"Leung","year":"2025","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.035_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104103","article-title":"Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.clbc.2026.07.035_bib0048","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2025.03.023","article-title":"Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive\/HER2-negative BC patients: results from the multicenter PALMARES-2 study","volume":"36","author":"Provenzano","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.07.035_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103257","article-title":"Survival outcomes of patients (pts) with metastatic lobular breast cancer (mLBC) receiving cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6i) and endocrine therapy (ET): a retrospective analysis","volume":"9","author":"Castellano","year":"2024","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.035_bib0050","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of Ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.035_bib0051","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with Ribociclib plus Fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:08:55Z","timestamp":1788948535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926001369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1526820926001369"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.035","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CDK4\/6i in the Underrepresented Histological Subtypes of HR\u00b1\/HER2- Metastatic Breast Cancer: A Real-World Cohort Study of Effectiveness and Safety","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}